Claim 1: the pharmaceutical composition of an oral drug, characterized in that its composition includes bendamusina or ester, salt or solution with acceptable efficacy as an active ingredient, and acceptable pharmaceutical precursor of a non-ionic surfactant, Requirement 12: medical conditions for the treatment of chronic lymphocytic leukemia, acute lymphocytic leukemia, chronic polio leukemia and polio leukemia according to any of the above requirements. Acute myeloid leukemiaHodgkin's disease, non Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small lung cancer and non small lung cancer. 13. Claim 13: a pharmaceutical ingredient according to any one of the above requirements, characterized in that the pharmaceutical ingredient is jointly managed with at least one additional active agent, which is used before, at the same time or after the pharmaceutical ingredient, A anthrax derivative was selected from a group of antibodies composed of CD20 specific antibodiesA basic vinca or platinum derivative Claim 14: the pharmaceutical ingredient referred to in claim 13, which is characterized by: the antibody with cd2o characteristic is rituximab； anthrax derivative is doxorobicina or daunorobicina； basic vinca is vincertina； platinum derivative is cisprino or carboplatino.Reivindicación 1: Una composición farmacéutica de administración oral, caracterizada porque la composición comprende bendamustina, o un éster, una sal o un solvato farmacéuticamente aceptable de ésta, como ingrediente activo, y un excipiente farmacéuticamente aceptable que es un agente tensioactivo no iónico, hidrofílico y farmacéuticamente aceptable.Reivindicación 12: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque se usa para tratar una condición médica que se selecciona entre la leucemia linfocítica crónica, la leucemia linfocítica aguda, la leucemia mielocítica crónica, la leucemia mielocítica aguda, la enfermedad de
